Food allergy and anaphylaxis

Abstract: Anaphylaxis is a severe and potentially life-threatening allergic reaction. There are numerous potential causes, with food allergy being the leading cause in children and the focus of this review. Most reactions involve an IgE-mediated mechanism, although non-IgE-mediated and nonimmunologic reactions can occur. Various cofactors to be discussed can place certain individuals at an increased risk of severe or fatal anaphylaxis. The clinical manifestations of anaphylaxis are broad and may involve multiple body systems. Diagnosis of food-related anaphylaxis is primarily based on signs and symptoms and supported, wherever possible, by identification and confirmation of a culprit food allergen. First-line treatment of anaphylaxis is intramuscular administration of epinephrine. Long-term management is generally focused on strict allergen avoidance and more recently on food desensitization using immunotherapy. This review provides an overview of anaphylaxis with a specific focus on food allergy.

Keywords: allergic reaction, food, trigger, epinephrine, avoidance, immunotherapy

Introduction

Anaphylaxis is defined as a serious allergic reaction that is rapid in onset and may cause death. Although human studies of the immunologic mechanisms of anaphylaxis are limited, most cases involve the interaction between an allergen and allergen-specific IgE bound to high-affinity IgE receptors on mast cells and basophils. The most common causes of IgE-dependent reactions include food, medications, Hymenoptera venom, and latex rubber.

Although less common, anaphylaxis can also involve non-IgE-mediated mechanisms, including IgG- and complement-mediated reactions, and direct mast cell and basophil activation in the absence of immunoglobulins. Potential causes include physical factors, such as exercise, cold and heat, and iatrogenic agents, including radiocontrast media and opiates. Regardless of the underlying mechanism or trigger, ultimately, there is activation of a signaling cascade resulting in mast cell and basophil degranulation. These cells release multiple mediators including histamine, tryptase, leukotrienes and prostaglandins, which lead to the clinical manifestations of anaphylaxis. Cytokines important in allergic disease, including TNF-α, IL-4, IL-5, IL-6, IL-10, and IL-13, activate complement and the kallikrein–kinin systems, further contributing to symptoms. Platelet-activating factor (PAF) and nitric oxide also appear to play a role. PAF is released during allergic reactions, and decreased activity of PAF acetylhydrolase, the enzyme that degrades PAF, has been associated with more severe anaphylaxis.

Non-IgE-mediated reactions are clinically indistinguishable and have similar acute
management despite their underlying mechanism. The objective of this paper is to review recently published evidence related to food allergy/anaphylaxis addressing prevalence, diagnostics, and treatment, including primary prevention and immunotherapy, in the past year (January 1, 2017, to January 4, 2018).

Methods
A database search (Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily, Ovid MEDLINE, and Versions(R) for articles, between January 1, 2017, and January 4, 2018) was conducted using the following key words: “anaphylaxis”, AND-ed “food allergy”.

Eligibility criteria
The following eligibility criteria were used for article inclusion: population: patients with food allergy and/or at risk for anaphylaxis; intervention: any approaches or protocols that incorporated a strategy for food allergy and anaphylaxis management; comparator: any studies irrespective of whether there was a comparator included in the study design; outcomes: any related to prevalence, diagnostics, and treatments including primary prevention and immunotherapy; and study design: experimental studies (e.g., randomized controlled trials [RCTs]), other experimental designs (e.g., non-randomized methods of assignment, controlled before–after studies, and interrupted time series), and observational studies (e.g., prospective or retrospective cohort, cross-sectional, and case–control). We excluded case reports, opinion-based reports (i.e., editorials, letters, and non-systematic or narrative reviews), and basic science or animal (nonhuman) studies.

Data synthesis
The analysis involved summarizing the data and presenting the results in a narrative synthesis. We prepared descriptive tables to give an overview of the included study characteristics. This manuscript was not designed to perform quantitative analysis, meta-analysis, or assessment of risk of bias.

Of 304 potentially relevant articles, a total of 15 articles with new insights on food allergy/anaphylaxis were selected. The majority of the studies (Table 1) consisted of retrospective studies (n=7), population-based cohort studies (n=2), clinical trials (n=3), cross-sectional surveys (n=1), prospective studies (n=1), and retrospective chart review (n=1).

The studies in the following overview address new insights on food allergy/anaphylaxis addressing prevalence, diagnostics, acute management, as well as primary prevention and immunotherapy (oral, epicutaneous, and sublingual routes).

Prevalence and characterization of food allergy/anaphylaxis
Increasing prevalence of anaphylaxis is supported by a recent US study conducted between January 1, 2001, and December 31, 2010, which examined records of 2,386 Olmsted County, MN, residents with a diagnosis of anaphylactic shock or related diagnoses (e.g., venom-related toxic events, medication reactions). A total of 631 cases that fit the clinical criteria of anaphylaxis were identified (median age 31 years). The overall incidence of anaphylaxis was 42/100,000 person-years. There was an increase in the overall incidence of anaphylaxis during the study period, with an average increase of 4.3%/year (P<0.001). A 9.8%/year increase in the incidence of food-related anaphylaxis was also noted.

Previous studies have reported food as the most common cause of anaphylaxis, which account for 30% of fatalities. Our review included a recent retrospective study of 4,777 electronic records (July 2002 to October 2013), which revealed that 730 (15%) patients evaluated in the Allergy and Immunology Department of Cleveland Clinic (median age 34 years; 73% adults, 59% females, 87% Caucasians) met the World Health Organization (WHO) definition of anaphylaxis. The top three causes were food (29.9%), venom (26.4%), and medications (13.3%), with venom being the most common in adults. In children, the most common foods were peanuts (32.0%), tree nuts (22.7%), milk (17.2%), and eggs (16.4%) as compared to adults where the most common foods were shellfish (34.4%), tree nuts (20.0%), and peanuts (12.2%).

In addition, a Canadian study (between April 2011 and February 2014) prospectively examined recurrence rates of anaphylaxis among 292 children (mean age 6.5 years) who attended an emergency department with anaphylaxis (two tertiary care pediatric hospitals and a third general hospital). The study reported an annual recurrence rate of 17.6% with food being the most common cause of these recurrences (84.6%).

A Canadian survey of self-reported food allergy showed an estimated food allergy prevalence of 6.9% in children (1–17 years) and 7.7% in adults (18+ years). Approximately 1.1% of respondents were allergic to peanut (PN). These estimates are higher than a recent electronic health record (Partners HealthCare, Boston, MA, USA) review that reported a 3.6% prevalence of food allergy (97,482 of 2,714,851 patients).
<table>
<thead>
<tr>
<th>Theme</th>
<th>Study</th>
<th>Objective</th>
<th>Setting/duration</th>
<th>Population</th>
<th>Design</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence</td>
<td>Gonzalez-Estrada et al6</td>
<td>To determine the pattern of anaphylaxis at a tertiary care referral center</td>
<td>Allergy and Immunology Clinic, Cleveland, OH, USA Electronic medical record review between 2002 and 2013</td>
<td>N = 730 patients with anaphylaxis</td>
<td>Retrospective study</td>
</tr>
<tr>
<td></td>
<td>Acker et al8</td>
<td>To determine the prevalence of food allergy and intolerance documented in the electronic health records (EHR) allergy module</td>
<td>Allergy data review with large health care organization’s EHR (Partners Healthcare, Boston, MA, USA) between 2000 and 2013</td>
<td>N = 97,482 patients with one or more food allergies or intolerances</td>
<td>Retrospective study</td>
</tr>
<tr>
<td></td>
<td>Leickly et al9</td>
<td>To confirm new observations on peanut allergy and answer current concerns that families and health care providers have about peanut allergy</td>
<td>Riley Peanut Registry; Riley Outpatient Center in Indianapolis; Indiana University North in Carmel, IN, USA; and Riley Children’s Specialists in Bloomington, IN, USA, between April 2011 and March 2016</td>
<td>N = 1,070 children with peanut allergy</td>
<td>Retrospective study</td>
</tr>
<tr>
<td></td>
<td>Lee et al4</td>
<td>To determine the incidence rate and causes of anaphylaxis during a 10-year period in Olmsted County, MN, USA</td>
<td>Rochester Epidemiology Project, Olmsted County, MN, USA, from 2001 to 2010</td>
<td>N = 631 cases of anaphylaxis</td>
<td>Population-based incidence study</td>
</tr>
<tr>
<td></td>
<td>O’Keefe et al10</td>
<td>To determine the recurrence rate of anaphylaxis in children medically attended in an emergency department (ED)</td>
<td>EDs, Outaouais region of Quebec, Canada, between April 2011 and February 2014</td>
<td>N = 292 children with anaphylaxis</td>
<td>Prospective cohort study</td>
</tr>
<tr>
<td>Diagnostics</td>
<td>Griffiths et al18</td>
<td>To review currently available diagnostic tests performance, how they are used, and how their use might be optimized to address unmet needs in allergy diagnosis</td>
<td>National Allergy Service for Wales at the University Hospital of Wales between April 2011 and March 2014</td>
<td>N = 1,434 females and 634 male patients; new referrals with clinical histories and presented with diagnostic difficulty</td>
<td>Retrospective study</td>
</tr>
<tr>
<td></td>
<td>Akuete et al22</td>
<td>To examine the epidemiology, symptoms, and treatment of clinical low-risk oral food challenges (OFCs) in the non-research setting</td>
<td>Data from five US food allergy centers: Texas Children’s Hospital Food Allergy Program (South); University of Pittsburgh School of Medicine, Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center (North Midwest); Riley Hospital for Children at Indiana University Health (Midwest); University of Washington School of Medicine, Northwest Asthma &amp; Allergy Center (Northwest); and Boston Children’s Hospital (Northeast); study conducted from January 1, 2008, to December 31, 2013</td>
<td>N = 6,377 open OFCs</td>
<td>Retrospective study</td>
</tr>
<tr>
<td></td>
<td>Chan et al23</td>
<td>To compare reaction profiles from food challenges and parent-reported reactions on accidental ingestion and assess predictors of severe reactions</td>
<td>HealthNuts study; birth cohort 2006–2009; Specialist Clinic at Melbourne’s Royal Children’s Hospital</td>
<td>2-month-old infants via their parents/guardians at childhood immunization sessions across the city of Melbourne, Australia</td>
<td>Longitudinal population-based cohort study</td>
</tr>
<tr>
<td></td>
<td>Yanagida et al24</td>
<td>To identify the risk factors for severe symptoms during OFC testing among high-risk patients</td>
<td>Sagamihara National Hospital, Japan Between June 2008 and June 2012</td>
<td>N = 393 patients ≥5 years old with anaphylactic history</td>
<td>Retrospective chart review</td>
</tr>
</tbody>
</table>

(Continued)
Allergic comorbid diseases have also been examined and are more prevalent in food allergic individuals. A US registry of PN allergic children (The Riley PN Registry), which reported the 5-year experience of 1,070 children (mean age 1 year), showed coexistent atopic dermatitis (65%), asthma (41%), and additional food allergies (68.7%).

Risk factors for anaphylaxis

Although our review did not capture recent studies examining this question, previous studies have shown that patient factors can increase the risk of severe or fatal anaphylaxis.

Examples of age-related factors include anaphylaxis in infancy, which is difficult to recognize as they cannot describe their symptoms, and risk-taking behaviors in teens and young adults including failure to avoid known triggers and carry an epinephrine autoinjector (EAI). In adults, chronic diseases such as asthma and cardiovascular diseases and their treatments with beta-blockers and angiotensin-converting enzyme inhibitors place them at an increased risk. Beta-blockers can increase reaction severity and specifically can make anaphylaxis more difficult to treat.

Mast cell disorders, including mastocytosis, and severe atopic diseases, including allergic rhinitis, can also increase the risk of severe or fatal anaphylaxis. Cofactors (external circumstances associated with more severe allergic symptoms) such as exercise, alcohol, nonsteroidal anti-inflammatory drugs (NSAIDs), acute infection, stress, and perimenstrual status can decrease allergen thresholds and amplify an anaphylactic reaction.

Factors that have been associated with fatality with regard to food-induced anaphylaxis include reactions to PN and tree nut (TN), delayed administration of epinephrine, a previous history of food allergy, asthma especially if poorly controlled, and age (more frequent in teenagers and young adults).
Diagnosis and clinical manifestations
The definition of anaphylaxis is based on an expert consensus and was published in 2006. Anaphylaxis is highly likely when any one of these three criteria are fulfilled: 1) sudden onset of an illness, with involvement of the skin, mucosal tissue, or both and at least one of respiratory compromise or reduced blood pressure or associated symptoms of end-organ dysfunction; 2) two or more of the following that occur rapidly after exposure to a likely allergen: skin/mucosal involvement, respiratory compromise, reduced blood pressure, or gastrointestinal (GI) symptoms; and 3) reduced blood pressure after exposure to a known allergen.

Cutaneous manifestations are reported in 80%-90% of all patients. In the Riley PN Registry, most reactions involved the skin (55%). In the absence of skin symptoms, anaphylaxis may be difficult to recognize and can occur in up to 20% of patients, specifically food or venom allergy. Anaphylaxis can range in severity from mild symptoms to very severe reactions, progressing within minutes to respiratory compromise or cardiovascular collapse and death. It is important to recognize that the clinical manifestations and severity of reactions are unpredictable and may differ from one patient to another and from one episode to another in the same patient.

Biphasic reactions can also occur, where patients experience a recurrence of symptoms within 72 hours of the initial anaphylactic event without re-exposure to the trigger. In a meta-analysis by Lee et al, the reported rate of biphasic reactions among the included studies was 4.6%. They noted that the risk of a biphasic reaction was greater with hypotension on presentation and an unknown inciting trigger. In general, it is recommended that all patients be observed for at least 4–6 hours after an anaphylactic reaction; however, this should be individually tailored.

Diagnostics
Laboratory studies may help establish a diagnosis of anaphylaxis. Increased levels of serum total tryptase and plasma histamine can be observed during or shortly after an acute anaphylactic episode. Tryptase levels peak 60–90 minutes after the onset of symptoms and remain elevated for at least 5 hours, whereas plasma histamine remains elevated for only 30–60 minutes. Normal levels do not rule out anaphylaxis and are usually present in patients with anaphylaxis to food and in those who are normotensive.

Skin prick tests (SPTs)
To identify a potential trigger (e.g., food, medications, insect stings), SPT is a reliable method. With regard to food allergy, a positive SPT has a sensitivity of ~90% and a specificity of ~50%. An SPT alone is not sufficient for diagnosis and must be interpreted in the context of the clinical history. The negative predictive value (NPV) of SPT is >95%, and a negative result essentially confirms the absence of IgE-mediated allergic reactivity.

Serum-specific IgE
A serum-specific IgE can be a useful alternative if an SPT cannot be performed or is unavailable. The ImmunoCAP method uses a fluorescent enzyme immunoassay to detect selective specific IgE antibodies. This is in contrast to Immuno Solid-phase Allergen Chip (ISAC) that measures specific IgE antibodies against multiple allergen components in a single assay. Higher concentrations of food-specific IgE levels correlate with an increasing likelihood of a clinical reaction but do not correlate well with reaction severity. In food-sensitized patients, specific IgE levels with >95% predictive risk values of a positive (failed) food challenge have been identified. The 95% positive predictive value (PPV) calculations depend on the population sampled and vary with specific prevalence rates in different geographic regions; hence, they are not completely generalizable. These levels are established for cow’s milk (CM) (>15 kU/L), egg (>7 kU/L), milk (>14 kU/L), TN (>15 kU/L), and fish (>20 kU/L).

Our review yielded a retrospective study of 2,068 new patient (69% female) referrals between April 4, 2011, and March 31, 2014, at the University Hospital of Wales, which revealed that in patients with nut allergy, the detection rates of SPT (56%) and ISAC (65%) were lower than those of ImmunoCAP (71%). In addition, ISAC had a higher detection rate (88%) than ImmunoCAP (69%) or SPT (33%) for the diagnosis of oral allergy syndrome (OAS). The higher detection rate of OAS was explained as being due to the lack of availability of component-resolved diagnostics (CRDs) in SPT, in particular pathogenesis-related (PR)-10. In this population, they concluded that although ImmunoCAP, ISAC, and SPT performed similarly for confirmation of food allergy and anaphylaxis, the ISAC was the most useful for confirmation of OAS.

CRD testing
CRD testing may predict the risk or severity of allergic reactions to specific food by measuring IgE to specific components and epitopes within an allergen source.
testing studies have shown that positive testing to the peanut component Ara h2 is more sensitive and specific than IgE to whole PN and the most consistent marker for predicting PN allergy. Serum IgE to Ara h2 has 60%–100% sensitivity and 60%–90% specificity in predicting reactivity. CRD testing can also identify cross-reactive specific components to other similar allergens from different pollen species or food items. For example, the PN component Ara h8 is positive in patients experiencing OAS.

**Oral food challenges (OFCs)**

If diagnostic tests remain unclear, an OFC may be considered for a suspected food and involves gradual feeding of the food to assess clinical reactivity. Although uncommon, recent studies report the rate of anaphylaxis during OFC to range from 2% to 3%. A Japanese retrospective study evaluated 393 patients (median age 8.3 years; ≥5 years old), defined as of high risk of a severe reaction [anaphylactic history or antigen-specific IgE (≥30 kU/L) to egg, milk, wheat, or peanut], and observed anaphylaxis (WHO definition) in 48% of cases during in-hospital OFC. Risk factors that were associated with severe symptoms were a history of a previous anaphylactic reaction and older age. This underscores the recommendation that OFCs must be conducted cautiously by trained health care providers, where resuscitation equipment is available, and anaphylaxis can be appropriately managed.

**Acute management**

Acute management of an IgE-mediated anaphylactic reaction starts with rapid assessment of airway, breathing, and circulation. First-line treatment is epinephrine administered intramuscularly into the lateral thigh. Treatment should be provided even if the diagnosis is uncertain since there are no absolute contraindications to the use of epinephrine.

The dose of epinephrine for the acute treatment of anaphylaxis is 0.01 mg/kg up to a maximum of 0.5 mg every 5–20 minutes as necessary. Glucagon should be considered in patients on beta-blockers. All individuals receiving emergency epinephrine must be transported to hospital immediately for evaluation and observation.

EAI devices should be stored avoiding temperature extremes and replaced before the expiration date. In a recent study of EpiPens, it was shown that although there was a gradual decline in concentration over time, >80% of their labeled concentration was retained 50 months after the expiration dates. The authors concluded that the expired EpiPens would likely still provide a beneficial pharmacologic response.

A significant number of states and Canadian provinces have allowed schools to stock EAI and train school staff on when to use and how to use EAIs. In a retrospective study of students (n=6,418,039) attending New York City district public schools, a total of 337 EAI administrations were reported between 2008 and 2013, highlighting an increasing incidence of 1.3 EAI administrations per year (from 3.7/100,000 students in 2008–2009 to 10.1/100,000 students in 2012–2013). A total of 42% of students were administered an EAI due to food-related anaphylaxis (84% PN allergy), and 58% of students treated for anaphylaxis were without a documented allergy. Treatment in these schools most commonly (52%) relied on stock supply of nonstudent-specific EAIs.

The most frequent cause of anaphylaxis in this study was found to be food. This emphasizes the importance of stock epinephrine in the management of anaphylaxis in the school setting and potentially in other high traffic public places.

The proportion of total students who provided documentation of physician-diagnosed food allergy increased significantly from 0.39% in 2007–2008 to 1.43% in 2012–2013 (P<0.001), as did the proportion of total students with a physician-prescribed EAI, which also increased significantly over the years of the study from 0.26% in 2007–2008 to 0.74% in 2012–2013 (P<0.001).

Recent findings from a global survey on food allergy revealed that 29% of respondents experienced an allergic reaction but did not administer an EAI for reasons ranging from not thinking the reaction was severe enough to fear of using it. This emphasizes the importance of educating patients and their caregivers on avoidance strategies, taking into consideration relevant triggers, age, activity, occupation, hobbies, residential conditions, access to medical care, patient’s anxiety, and the appropriate use of EAIs. All patients at risk of anaphylaxis must always carry an EAI and wear medical identification (i.e., MedicAlert bracelet/necklace). An anaphylaxis action plan outlining the recognition and treatment of an anaphylactic reaction as well as the trigger allergen should be developed and made available to the appropriate people (e.g., caregivers, daycare providers, teachers, employers).
Since food avoidance still plays a significant role in food allergy management, a well-balanced elimination diet will keep an individual free of symptoms while maintaining nutritional status. An exception to strict avoidance is CM and egg allergy. Previous studies have shown that the majority of CM-allergic (74%) and egg-allergic (71%) children can tolerate baked milk and baked egg, respectively, which increases the rate of oral tolerance to these food items.36,37

**Immunotherapy and desensitization**

Food allergy research as well as recent media attention has focused on food desensitization using immunotherapy as a means of food allergy treatment. With immunotherapy, the aim is to first achieve desensitization (temporary) with the ultimate goal being tolerance (permanent) to the allergen. Oral, epicutaneous, and sublingual routes of food desensitization administration have continued to be examined as potential treatments and are primarily available through research protocols as there are currently no approved products for desensitization in the USA and Canada.

**Oral immunotherapy (OIT)**

In most OIT protocols, food is gradually introduced under medical supervision, with increases in the food dose occurring every 2 weeks. This is continued until a predefined maintenance dose is reached, which is then continued for months to years to maintain desensitization. With the exception of the biweekly dose escalations, daily dosing is done at home. Efficacy is determined by an OFC to the food in question. While multiple randomized control trials have confirmed that OIT is often effective for inducing desensitization (temporary unresponsiveness) and increasing thresholds to various food allergens, tolerance (sustained unresponsiveness) has not generally been achieved. The rate of successful desensitization reported in studies ranges from 35% to 100% (intention to treat) and varies based on the patient’s age, food, chosen allergens, tolerance (sustained unresponsiveness) and increasing thresholds to various food allergens, etc.) can influence the risk of acute AEs with oral food desensitization, an important consideration in ensuring safety and efficacy when carrying out such therapies.38 OIT studies have reported improved quality of life and less anxiety for those who have completed this process.38

There are currently no approved OIT therapies; however, recent findings of the Peanut AR101 (Aimmune Therapeutics, Brisbane CA, USA) Phase II clinical trial of 55 peanut allergic subjects (4–26 years old) concluded that AR101 (n=29) significantly reduced symptom severity during exit DBPCFCs and modulated peanut-specific cellular and humoral immune responses versus placebo (n=26). GI symptoms were the most common treatment-related AEs, with six AR101 subjects withdrawing (patient dose ranged between 6 and 80 mg during the escalation phase), four subjects due to recurrent GI AEs.40

**Epicutaneous immunotherapy**

In epicutaneous immunotherapy, the food is contained in a patch, which is applied to the skin. A randomized double-blind, placebo controlled trial compared two doses of Viaskin Peanut 100 μg (n=24) and Viaskin Peanut 25 μg (n=25) versus placebo (n=25) in children and young adults with peanut allergy (aged 4–26 years; physician-diagnosed peanut allergy (aged 4–25 years; physician-diagnosed peanut allergy). In a randomized, placebo-controlled trial, Vickery et al.39 investigated the efficacy of peanut OIT in young children aged 9–36 months using a low-dose (300 mg/day peanut protein) and high-dose (3,000 mg/day) OIT. They demonstrated that overall 78% of patients achieved sustained unresponsiveness (defined as the ability to consume 5 g of peanut protein without dose-limiting symptoms during an exit double-blind, placebo-controlled food challenge [DBPCFC]) to peanut 4 weeks after stopping OIT and reintroduced peanut into the diet.39 Although this is the highest rate reported to date, patients should be aware that this is still not synonymous with cure, given the short duration of follow-up. Study authors suggest that allergic responses may be more easily modified in young children, but ongoing studies are required to strengthen this hypothesis. There were no treatment-related, severe adverse events (AEs), hospitalizations, or deaths. A total of 85% of the subjects experienced AEs (rash, skin, sneezing/congestion, hives, rash, GI symptoms) that resolved without treatment or with oral antihistamines only (47%). A total of 10 subjects withdrew from the study due to AEs. Epinephrine was not administered during dose-escalation visits but was used once at home dosing.

It has also been observed that cofactors (exercise, infection, etc.) can influence the risk of acute AEs with oral food desensitization, an important consideration in ensuring safety and efficacy when carrying out such therapies.38 OIT studies have reported improved quality of life and less anxiety for those who have completed this process.38

In epicutaneous immunotherapy, the food is contained in a patch, which is applied to the skin. A randomized double-blind, placebo controlled trial compared two doses of Viaskin Peanut 100 μg (n=24) and Viaskin Peanut 25 μg (n=25) versus placebo (n=25) in children and young adults with peanut allergy (aged 4–26 years; physician-diagnosed peanut allergy). In a randomized, placebo-controlled trial, Vickery et al.39 investigated the efficacy of peanut OIT in young children aged 9–36 months using a low-dose (300 mg/day peanut protein) and high-dose (3,000 mg/day) OIT. They demonstrated that overall 78% of patients achieved sustained unresponsiveness (defined as the ability to consume 5 g of peanut protein without dose-limiting symptoms during an exit double-blind, placebo-controlled food challenge [DBPCFC]) to peanut 4 weeks after stopping OIT and reintroduced peanut into the diet.39 Although this is the highest rate reported to date, patients should be aware that this is still not synonymous with cure, given the short duration of follow-up. Study authors suggest that allergic responses may be more easily modified in young children, but ongoing studies are required to strengthen this hypothesis. There were no treatment-related, severe adverse events (AEs), hospitalizations, or deaths. A total of 85% of the subjects experienced AEs (rash, skin, sneezing/congestion, hives, rash, GI symptoms) that resolved without treatment or with oral antihistamines only (47%). A total of 10 subjects withdrew from the study due to AEs. Epinephrine was not administered during dose-escalation visits but was used once at home dosing.

It has also been observed that cofactors (exercise, infection, etc.) can influence the risk of acute AEs with oral food desensitization, an important consideration in ensuring safety and efficacy when carrying out such therapies.38 OIT studies have reported improved quality of life and less anxiety for those who have completed this process.38

There are currently no approved OIT therapies; however, recent findings of the Peanut AR101 (Aimmune Therapeutics, Brisbane CA, USA) Phase II clinical trial of 55 peanut allergic subjects (4–26 years old) concluded that AR101 (n=29) significantly reduced symptom severity during exit DBP-CFCs and modulated peanut-specific cellular and humoral immune responses versus placebo (n=26). GI symptoms were the most common treatment-related AEs, with six AR101 subjects withdrawing (patient dose ranged between 6 and 80 mg during the escalation phase), four subjects due to recurrent GI AEs.40
of VP250 participants \( (P=0.003) \). It was also noted that the highest responses were in children 11 years old or younger.\(^4\) In the extension study that included 18 children (6–11 years) treated with 250 \( \mu \)g PN patches for 3 years, there was a trend toward better treatment responses (83.3\%) with long-term therapy.\(^2\) The adherence rate in these studies was observed to be \( \geq 95\% \). In addition, no serious AEs or epinephrine use was reported. Most AEs were mild to moderate, related to the application site, and decreased in both severity and frequency over time.

**Sublingual immunotherapy (SLIT)**

Desensitization by SLIT utilizes dissolvable tablets or liquid allergen extracts that are placed under the tongue daily. SLIT uses lower doses than OIT and is associated with less AEs, but is generally not as effective.\(^38\)

**Food allergy prevention**

**Early introduction of food**

There have been a number of studies centered on food allergy prevention. Infants with a first-degree relative with a history of allergic disease (allergic rhinitis, asthma, eczema, or food allergy) is at a greater risk of developing food allergy.\(^43\)

A number of observational studies have suggested that the early and regular consumption of PN, egg, or CM may prevent the development of food allergy.\(^44\)–\(^46\) The Learning Early About Peanut (LEAP) trial, a landmark RCT, showed that in high-risk infants (defined as those with severe eczema and/or egg allergy), early introduction of PN between 4 and 11 months of age resulted in a significant reduction in PN allergy. The relative risk reduction was 81\% at 5 years of age.\(^47\) The Persistence of Oral Tolerance to Peanut (LEAP-On) follow-up study investigated whether the rate of PN allergy in participants who had consumed PN in the primary trial would remain low after 12 months of PN avoidance.\(^48\) It showed that the benefits of early PN introduction persisted after a 12-month period of PN avoidance. Based on these findings, the American Academy of Pediatrics has endorsed the updated guidelines regarding high-risk infants (severe eczema and/or egg allergy) and have recommended early introduction of PN between 4 and 6 months of age, with PN sIgE testing prior to introduction. In these high-risk infants (defined as those with severe eczema and/or egg allergy), early introduction of PN between 4 and 6 months of age resulted in a significant reduction in PN allergy. The relative risk reduction was 81\% at 5 years of age.\(^47\) The Persistence of Oral Tolerance to Peanut (LEAP-On) follow-up study investigated whether the rate of PN allergy in participants who had consumed PN in the primary trial would remain low after 12 months of PN avoidance.\(^48\) It showed that the benefits of early PN introduction persisted after a 12-month period of PN avoidance. Based on these findings, the American Academy of Pediatrics has endorsed the updated guidelines regarding high-risk infants (severe eczema and/or egg allergy) and have recommended early introduction of PN between 4 and 6 months of age, with PN sIgE testing prior to introduction. In these high-risk infants, if a serum-specific IgE is used to screen and is positive (PN sIgE \( \geq 0.35 \) kU/L), referral to an allergy specialist for PN SPT and possible supervised feeding are advised. If SPTs are used to screen, results of 0–2 mm have a 95\% NPV and home or office introduction is recommended. A 3–7 mm positive skin test has a moderate to high risk and supervised office introduction or graded oral challenge is recommended. Finally, if the SPT is \( \geq 8 \) mm, they are likely allergic and should be referred to an allergy specialist. Those at a lower risk (mild to moderate eczema) are recommended to introduce PN at \( \approx 6 \) months taking into account family/cultural preferences. In addition, low-risk (no eczema or food allergy) infants should introduce PN with other solids according to family/cultural preferences.\(^49\)

Application of these findings remains uncertain as there is no universal agreement on the definition of high-risk infants.\(^50\) It is also not clear if these positive outcomes can be generalized to the general population who are not necessarily at high risk.\(^51\)

The Enquiring about Tolerance (EAT) trial examined whether early introduction of six allergenic food items (PN, egg, CM, sesame, whitefish, and wheat) in exclusively breastfed infants would reduce the prevalence of food allergy by the age of 3 years. In the treatment group, food items were introduced at 3 months of age and continued until 1 year when they were compared to infants who were exclusively breastfed for 6 months (standard introduction group).\(^52\) The intention-to-treat analysis revealed a 20\% reduction in the prevalence of food allergy in the early introduction group, not statistically significant, but likely related the high rate of nonadherence to the dietary protocol; the per protocol analysis showed a significant difference.

The Hen’s Egg Allergy Prevention (HEAP) study (randomized, placebo-controlled trial) evaluated the efficacy and safety of early hen’s egg introduction at age 4–6 months to prevent hen’s egg allergy in the general population. Of 406 children screened, 383 non-sensitized infants were randomized to receive either verum (egg white powder) or placebo (rice powder). The study in contrast found no evidence that consumption of hen’s egg starting at 4–6 months of age prevented hen’s egg sensitization or allergy.\(^53\)

**Eczema prevention**

A personal history of eczema is one of the strongest risk factors for food allergy. In a study by Martin et al, one in five infants with eczema had challenge-confirmed allergy to egg white, PN, or sesame by 12 months of age, compared with only one in 25 infants without eczema. In addition, those with earlier age of onset eczema (first 3 months of life) and increasing severity of eczema (based on treatment required for control) were more likely to develop a food allergy.\(^24\)

Skin barrier dysfunction is a feature of eczema and is thought to play an important role in allergic sensitization and subsequent progression to food allergy and other allergic
Therefore, prevention of eczema in early life may prevent development of future food allergy and other allergic diseases. One of the primary targets for eczema prevention is improving skin barrier integrity through regular application of a moisturizing cream in infants. An RCT supported the efficacy of this intervention for reducing eczema with significant relative risk reductions ranging from 32% to 50%. However, it is yet to be determined whether prevention of eczema in early life will subsequently prevent allergic sensitization and food allergy.

**Summary**

Anaphylaxis is an acute and potentially life-threatening allergic reaction. There are a variety of causes; however, food allergy continues to be the leading cause of anaphylaxis and the predominant cause in children. Early recognition and subsequent treatment with epinephrine are critical. Although current management still advises strict avoidance of some foods, new advances in treatment are on the horizon, most notably in the area of PN desensitization. New recommendations for primary prevention of PN and possibly other food allergens will hopefully disrupt the rising prevalence of this important clinical problem.

**Study limitations**

The literature review did not limit our search to study designs engineered to assess the best quality of evidence. Our broad objective was to highlight current evidence on food allergy and anaphylaxis. In addition, we did not address potential sources of variability between the studies by conducting quality assessment and critical appraisal.

**Acknowledgment**

The authors did not receive compensation nor was the content of the article influenced in any way. Adamis Pharmaceuticals paid publication fees for the articles in this special issue on anaphylaxis.

**Disclosure**

SW is an advisory board member for Pfizer Canada and serves as a medical advisor to Food Allergy Canada. The authors report no other conflicts of interest in this work.

**References**


